Abstract
The serine/threonine protein phosphatase PP1 mediates the dephosphorylation of phosphorylated eukaryotic translation initiation factor 2 subunit α (p-eIF2α), a central regulator of protein synthesis. This study investigated the protective effects of PP1-12, a PP1 inhibitor, against tunicamycin (TM)-induced apoptosis in cultured cardiomyocytes and in an in vivo model of ischemia/reperfusion (I/R) injury. Results indicate that PP1-12 protects cell viability, induces eIF2α phosphorylation, and downregulates pro-apoptotic markers like CHOP and cleaved caspase-12, effectively reducing myocardial infarction area.
Introduction
Cardiomyocytes are highly susceptible to damage from ischemia/reperfusion (I/R) injury, which triggers severe Endoplasmic Reticulum (ER) stress. This stress leads to the accumulation of misfolded proteins and eventually initiates programmed cell death (apoptosis). A critical regulator in this pathway is the eukaryotic translation initiation factor 2 subunit α (eIF2α). When phosphorylated (p-eIF2α), it transiently inhibits protein synthesis, allowing the cell to recover from ER stress. However, the enzyme Protein Phosphatase 1 (PP1) dephosphorylates p-eIF2α, terminating this protective signal. This study explores PP1-12 as a novel pharmacological agent to inhibit PP1 and sustain the protective effects of p-eIF2α.
Methods and Materials
Chemical Synthesis and Screening
Researchers synthesized 95 molecules based on the structure of salubrinal, a known but toxic PP1 inhibitor. Through structure-activity relationship (SAR) studies, PP1-12 was identified as a potent candidate with improved solubility and lower toxicity.
Experimental Models
- In Vitro: Neonatal rat cardiomyocytes were treated with Tunicamycin (TM) to induce ER stress. Cells were pre-treated with varying concentrations of PP1-12 (0.3, 1, and 3 µmol/l). Cell viability was measured via ATP bioluminescence.
- In Vivo: Adult Sprague-Dawley rats underwent 30 minutes of left anterior descending coronary artery (LAD) ligation followed by 2 hours of reperfusion. Treatment groups received 1, 3, or 10 mg/kg/day of PP1-12.
Results
PP1-12 Sustains eIF2α Phosphorylation
Western blot analysis confirmed that PP1-12 treatment significantly increased the levels of p-eIF2α in cardiomyocytes exposed to TM. By preventing the dephosphorylation of eIF2α, PP1-12 maintains the cell's adaptive stress response.
Protection Against Apoptosis and Tissue Damage
In cellular models, PP1-12 (3 µmol/l) reduced the expression of the pro-apoptotic protein CHOP by approximately 50%. In the animal model, the most significant protection was observed at the 10 mg/kg/day dose. The myocardial infarct area was reduced from 20.7% in the vehicle group to just 4.5% in the high-dose PP1-12 group. Furthermore, PP1-12 treatment led to a decrease in cleaved caspase-12, a marker specifically associated with ER-stress-induced apoptosis.
Discussion
The findings demonstrate that PP1-12 effectively protects cardiomyocytes from both chemical-induced ER stress and physiological I/R injury. The primary mechanism involves the inhibition of PP1, which prevents the dephosphorylation of p-eIF2α and subsequently downregulates the CHOP/caspase-12 apoptotic pathway.
While these results are promising, further research is needed to map the exact molecular docking of PP1-12 and assess potential off-target effects on other phosphatases. Long-term safety profiles and efficacy in larger mammalian models are necessary steps before clinical translation can be considered.
Summary updated